January 23, 2026

Helping Patients Weigh Medical Advice from Friends and Family

When patients receive outside medical opinions from friends, family or online sources, how can physicians respond? A Keck Medicine of USC medical oncologist shares his approach.

Keck Medicine of USC

January 22, 2026

Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients...

The ASCO Post

January 22, 2026

Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?

At the American College of Surgeons Clinical Congress 2025, a session on integrating fallopian tube removal into general surgery practice explored the need for greater awareness of offering the proced...

The ASCO Post

January 22, 2026

Investigating the Mechanisms of Cardiovascular Adverse Events Linked to Certain Cancer Treatments

The true upside of the many advances in cancer treatment is clear. Approximately 18.6 million people in the United States have a history of cancer, and the number of cancer survivors is expected to ex...

The ASCO Post

January 21, 2026

Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC

In the final analysis of a phase III trial (POTOMAC) reported in The Lancet, De Santis et al found that the addition of durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance improved ...

The ASCO Post

January 21, 2026

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

A perioperative regimen of enfortumab vedotin-ejfv plus pembrolizumab significantly improved survival and pathologic complete response rates compared to radical cystectomy alone in patients with muscl...

The ASCO Post

January 16, 2026

New CAR T-Cell Therapy Shows Promise as ‘Magic Bullet’ for Patients with Relapsed/Refractory AML — Even After Transplant

A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., is evaluating a new chimeric antigen receptor (CAR) T-cell therapy that could dramatically transform the treatment of relapsed or refractory acute myeloid leukemia (AML).

Roswell Park Comprehensive Cancer Center

January 15, 2026

Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?

Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's ris...

The ASCO Post

January 15, 2026

Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma

In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was ...

The ASCO Post